ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2017
Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Beneficial effects of melatonin on liver fibrosis: A systematic review of current biological evidence.Journal of cellular physiology · 2022Pooled it
- Molecular Mechanisms of Fibrosis in Cholestatic Liver Diseases and Regenerative Medicine-Based Therapies.Cells · 2024Review
- Melatonin attenuates cholestatic liver injury via inhibition of the inflammatory response.Molecular and cellular biochemistry · 2023Article
- The zhuyu pill relieves rat cholestasis by regulating the mRNA expression of lipid and bile metabolism associated genes.Frontiers in pharmacology · 2023Article
- Endothelin Signaling Mediates Biliary-Endothelial Crosstalk in Primary Sclerosing Cholangitis.Cellular and molecular gastroenterology and hepatology · 2023Article
- Review
- Developmental programming: Impact of prenatal bisphenol-A exposure on liver and muscle transcriptome of female sheep.Toxicology and applied pharmacology · 2022Article
- Melatonin: a pleiotropic hormone as a novel potent therapeutic candidate in arsenic toxicity.Molecular biology reports · 2021Review
- The Role of microRNAs in Cholangiocarcinoma.International journal of molecular sciences · 2021Review
- Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.Hepatology (Baltimore, Md.) · 2021Observational
- Molecular Mechanisms of Melatonin-Mediated Cell Protection and Signaling in Health and Disease.Pharmaceutics · 2021Review
- Melatonin Protects Cholangiocytes from Oxidative Stress-Induced Proapoptotic and Proinflammatory Stimuli via miR-132 and miR-34.International journal of molecular sciences · 2020Article
- Biliary damage and liver fibrosis are ameliorated in a novel mouse model lacking l-histidine decarboxylase/histamine signaling.Laboratory investigation; a journal of technical methods and pathology · 2020Article
- Amelioration of Large Bile Duct Damage by Histamine-2 Receptor Vivo-Morpholino Treatment.The American journal of pathology · 2020Article
- Melatonin and circadian rhythms in liver diseases: Functional roles and potential therapies.Journal of pineal research · 2020Review
- Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.Hepatology (Baltimore, Md.) · 2020Article
- Review
- Melatonin Inhibits Transforming Growth Factor-β1-Induced Epithelial-Mesenchymal Transition in AML12 Hepatocytes.Biology · 2019Article
- Possible application of melatonin treatment in human diseases of the biliary tract.American journal of physiology. Gastrointestinal and liver physiology · 2019Review
- Protective role of melatonin in early-stage and end-stage liver cirrhosis.Journal of cellular and molecular medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
Melatonin therapy or prolonged exposure to complete darkness reduces biliary hyperplasia and liver fibrosis in bile-duct-ligated (BDL) rats; however, no information exists in primary sclerosing cholangitis (PSC). Thus, we aimed to determine the therapeutic effects of prolonged dark therapy or melatonin administration on hepatic fibrosis in the multidrug resistance gene 2-knockout (Mdr2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.